These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25894268)

  • 21. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
    Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low glucose suspend: ready for prime time?
    Hirsch IB
    Diabetes Technol Ther; 2012 Mar; 14(3):201-2. PubMed ID: 22320711
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of sensor-augmented insulin pump in patient with diabetes and cystic fibrosis: evidence for improvement in metabolic control.
    Klupa T; Małecki M; Katra B; Cyganek K; Skupień J; Kostyk E; Pietrzyk J; Sieradzki J
    Diabetes Technol Ther; 2008 Feb; 10(1):46-9. PubMed ID: 18275362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
    Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
    Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
    Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
    Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological aspects of closed loop insulin delivery for type 1 diabetes.
    Uduku C; Oliver N
    Curr Opin Pharmacol; 2017 Oct; 36():29-33. PubMed ID: 28802779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Closed loop insulin delivery in diabetes.
    Battelino T; Omladič JŠ; Phillip M
    Best Pract Res Clin Endocrinol Metab; 2015 Jun; 29(3):315-25. PubMed ID: 26051293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery.
    Weiss R; Garg SK; Bergenstal RM; Klonoff DC; Bode BW; Bailey TS; Thrasher J; Schwartz F; Welsh JB; Kaufman FR;
    J Diabetes Sci Technol; 2015 May; 9(5):1016-20. PubMed ID: 25986629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 Diabetes.
    Steineck I; Ranjan A; Nørgaard K; Schmidt S
    J Diabetes Sci Technol; 2017 Jan; 11(1):50-58. PubMed ID: 28264173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.
    Ly TT; Weinzimer SA; Maahs DM; Sherr JL; Roy A; Grosman B; Cantwell M; Kurtz N; Carria L; Messer L; von Eyben R; Buckingham BA
    Pediatr Diabetes; 2017 Aug; 18(5):348-355. PubMed ID: 27191182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current topics in glycemic control by wearable artificial pancreas or bedside artificial pancreas with closed-loop system.
    Hanazaki K; Munekage M; Kitagawa H; Yatabe T; Munekage E; Shiga M; Maeda H; Namikawa T
    J Artif Organs; 2016 Sep; 19(3):209-18. PubMed ID: 27142278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IQWiG Reanalyzes and Raises Questions About an Article by Ly et al Which Concluded Low Glucose Suspend Is Very Beneficial.
    Heinemann L; Hermanns N
    J Diabetes Sci Technol; 2015 Aug; 10(1):185-90. PubMed ID: 26251370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes.
    Del Favero S; Place J; Kropff J; Messori M; Keith-Hynes P; Visentin R; Monaro M; Galasso S; Boscari F; Toffanin C; Di Palma F; Lanzola G; Scarpellini S; Farret A; Kovatchev B; Avogaro A; Bruttomesso D; Magni L; DeVries JH; Cobelli C; Renard E;
    Diabetes Obes Metab; 2015 May; 17(5):468-76. PubMed ID: 25600304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of SmartGuard Technology in the Prevention of Nocturnal Hypoglycemia After Prolonged Physical Activity.
    Petruzelkova L; Pickova K; Sumnik Z; Soupal J; Obermannova B
    Diabetes Technol Ther; 2017 May; 19(5):299-304. PubMed ID: 28520532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin pumps: from inception to the present and toward the future.
    Alsaleh FM; Smith FJ; Keady S; Taylor KM
    J Clin Pharm Ther; 2010 Apr; 35(2):127-38. PubMed ID: 20456732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial.
    Nimri R; Muller I; Atlas E; Miller S; Fogel A; Bratina N; Kordonouri O; Battelino T; Danne T; Phillip M
    Diabetes Care; 2014 Nov; 37(11):3025-32. PubMed ID: 25078901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiniMed 530G: an insulin pump with low-glucose suspend automation.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):97-8. PubMed ID: 24322663
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimal glycaemic control during caesarean section provided by sensor-augmented pump therapy with predictive low-glucose suspend function.
    Beato-Víbora PI; Arroyo-Díez FJ
    Acta Diabetol; 2018 Oct; 55(10):1083-1085. PubMed ID: 29987593
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial.
    Ly TT; Nicholas JA; Retterath A; Lim EM; Davis EA; Jones TW
    JAMA; 2013 Sep; 310(12):1240-7. PubMed ID: 24065010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.